Is there a risk for semaglutide misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) pharmacovigilance dataset
S Chiappini, R Vickers-Smith, D Harris… - Pharmaceuticals, 2023 - mdpi.com
Recent media reports commented about a possible issue of the misuse of antidiabetics
related to molecules promoted as a weight-loss treatment in non-obese people. We …
related to molecules promoted as a weight-loss treatment in non-obese people. We …
Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system
Y Shu, X He, P Wu, Y Liu, Y Ding, Q Zhang - Frontiers in public health, 2022 - frontiersin.org
Background Semaglutide was approved for treatment of type 2 diabetes mellitus (T2DM)
and chronic weight management in obesity or overweight adults. However, real-world data …
and chronic weight management in obesity or overweight adults. However, real-world data …
Difference in gastrointestinal risk associated with use of GLP-1 receptor agonists: a real-world pharmacovigilance study
Y Zhou, M Chen, L Liu, Z Chen - Diabetes, Metabolic Syndrome …, 2022 - Taylor & Francis
Background Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are promising
weight-loss drugs, but real-world data concerning the liability of GLP-1RAs in …
weight-loss drugs, but real-world data concerning the liability of GLP-1RAs in …
[HTML][HTML] Safety of semaglutide
MM Smits, DH Van Raalte - Frontiers in endocrinology, 2021 - frontiersin.org
The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently
approved agent of this drug class, and the only GLP-1RA currently available as both …
approved agent of this drug class, and the only GLP-1RA currently available as both …
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes
VR Aroda, U Erhan, P Jelnes, JJ Meier… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aim Glucagon‐like peptide‐1 receptor agonists improve glycaemic control: some are now
available as oral and subcutaneous formulations, and some have indications for reducing …
available as oral and subcutaneous formulations, and some have indications for reducing …
Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
Introduction Gastrointestinal (GI) adverse events (AEs) are the most common AEs with
glucagon-like peptide-1 receptor agonists (GLP-1RAs). Weight loss (WL) is slightly greater …
glucagon-like peptide-1 receptor agonists (GLP-1RAs). Weight loss (WL) is slightly greater …
The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting …
RS McIntyre, RB Mansur, JD Rosenblat… - Expert Opinion on …, 2024 - Taylor & Francis
ABSTRACT Introduction Recently, the European Medicines Agency (EMA) received reports
of suicidal thoughts and self-injury associated with glucagon-like peptide-1 receptor …
of suicidal thoughts and self-injury associated with glucagon-like peptide-1 receptor …
Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss
Methods| We used a random sample of 16 million patients (2006-2020) from the PharMetrics
Plus for Academics database (IQVIA), a large health claims database that captures 93% of …
Plus for Academics database (IQVIA), a large health claims database that captures 93% of …
Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and …
Aim We evaluated gastrointestinal (GI) adverse events (AEs) with once‐weekly semaglutide
2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL) …
2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL) …
Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials
DG Yin, LL Ding, HR Zhou, M Qiu, XY Duan - Endocrine Journal, 2021 - jstage.jst.go.jp
The PIONEER and SUSTAIN serial trials are designed to assess the efficacy outcomes with
semaglutide in patients with type 2 diabetes, but are not powered to assess various safety …
semaglutide in patients with type 2 diabetes, but are not powered to assess various safety …